Bimekizumab improves patient-reported outcomes and work productivity in patients with psoriatic arthritis: 1-Year results from two Phase 3 studies
J Rheumatol 2025. Epub ahead of print doi: 10.3899/jrheum.2024-0923
Gladman et al. assessed the impact of bimekizumab over 1 year on patient-reported symptoms, HRQoL, and work productivity in patients with PsA who were bDMARD-naïve or TNF-IR. The study showed that bimekizumab treatment resulted in sustained improvements across multiple domains, including pain, fatigue, physical function, and work impairment.
The study utilised data from the BE OPTIMAL and BE COMPLETE Phase 3 trials and their OLE, BE VITAL, to evaluate PROs over 52/40 weeks. Participants received subcutaneous bimekizumab 160mg Q4W. At Wk16, patients receiving placebo switched to bimekizumab.
Keywords:
